Jump to content

Repligen

Add links
From Wikipedia, the free encyclopedia
Repligen Corporation
Company type
Public
Nasdaq: RGEN
S&P 400 Component
IndustryBiotechnology

Pharmaceutical

Laboratory equipment
Founded1981; 45 years ago (1981)
FoundersAlexander Rich
Paul Schimmel
Headquarters
Waltham, Massachusetts
,
United States
Key people
Olivier Loeillot (president and CEO)[1]
ProductsMaterials used in the manufacture of biological drugs
RevenueIncreaseUS$738 million (2025)
Number of employees
c. 2,000 (2025)
Websiterepligen.com

Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.[2][3]

History

[edit]

Repligen was founded in 1981 by Alexander Rich[4][5] and Paul Schimmel and was incorporated in Delaware. It has a headquarters and manufacturing facility in Waltham, Massachusetts.[6]

In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013.[7]

In 2011, Repligen acquired bioproduction assets from Novozymes, which doubled the company's bioprocessing capabilities.[7]

Before 2012, Repligen maintained dual capabilities in developing pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business).[7] A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures.[8]

Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application (NDA) submission; a Marketing Authorization Application had been submitted in parallel to the EMA.[2]

At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer.[7] This divestment included licensing rights to two patents to Pfizer.[9][10][11]

At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$2,000,000 and future milestone and royalty payments.[2][12]

Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions[13] and Tantti Laboratory Inc.[14] among others.[15][16]

As of 2024, the company's President and Chief Executive Officer is Olivier Loeillot.[17]

As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.[18]

Products and services

[edit]

Repligen develops and manufactures products used in bioprocessing and biological drug manufacturing. The company was a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry, which accounted for most of its sales in the early 2010s.[7][19] It has since expanded into other areas, including filtration and fluid management, chromatography, process analytics and proteins, serving biologics such as monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA products, and cell and gene therapies. Some of its better-known product families include XCell ATF perfusion systems,[20][21] OPUS pre-packed chromatography columns,[22][23] KrosFlo tangential flow filtration systems,[24][25] and CTech variable pathlength spectroscopy systems such as SoloVPE and FlowVPE.[26][27] Many of these expansions have occurred through acquisitions, including BioFlash (OPUS),[19] Refine Technology (ATF),[28] ARTeSYN Biosolutions,[29] and others.[15][7]

Growth factor products and the native form of Protein A and recombinant Protein A are manufactured in Sweden; assembly of the OPUS chromatography product line is done in the United States.[9]

References

[edit]
  1. ^ https://investors.repligen.com/press-releases/news-details/2024/Repligen-Announces-CEO-Transition-Plan/default.aspx
  2. ^ a b c Repligen 2013 10-K 2014, p. 2.
  3. ^ Nasdaq: RGEN
  4. ^ Motley Fool 2014.
  5. ^ Forbes 2014.
  6. ^ Repligen 2013 10-K 2014, p. 19.
  7. ^ a b c d e f Repligen 2013 10-K 2014, p. 1.
  8. ^ Repligen 2013 10-K 2014, p. 4.
  9. ^ a b Repligen 2013 10-K 2014, p. 7.
  10. ^ US 7888366  "2,4-diaminoquinazolines for spinal muscular atrophy"
  11. ^ US 7985755  "2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY"
  12. ^ Gen. Eng. Biotechnol. News 2014.
  13. ^ "Repligen | Inspiring advances in bioprocessing". Repligen. Retrieved 2025-10-10.
  14. ^ "Repligen Announces Agreement to Acquire Chromatography Innovator Tantti". www.tantti.com. 2024-07-29. Retrieved 2025-10-10.
  15. ^ a b "Repligen (RGEN) to Acquire Fluid Management Company Metenova". Nasdaq.com. September 27, 2023.
  16. ^ "Repligen lays down $70m to buy PAT tools from 908 Devices". BioProcess International. Retrieved 2025-10-10.
  17. ^ "Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance" (PDF). Repligen. 2026-05-05. Archived from the original (PDF) on 2026-05-15.
  18. ^ "Repligen 2025 Annual Report" (PDF). Repligen. 2026-02-26. Archived from the original (PDF) on 2026-05-15.
  19. ^ a b Repligen 2013 10-K 2014, p. 3.
  20. ^ Nie, Jianqi; Sun, Yang; Feng, Kai; Huang, Lingling; Li, Ye; Bai, Zhonghu (2022-03-18). "The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process". Vaccine. 40 (13): 2036–2043. doi:10.1016/j.vaccine.2022.02.024. ISSN 1873-2518. PMC 8863426. PMID 35216843.
  21. ^ Weinberger, Maria E.; Schoch, Luis; Kulozik, Ulrich (2022-10-29). "New technical concept for alternating tangential flow filtration in biotechnological cell separation processes". Biotechnology Progress. 39 (2). doi:10.1002/btpr.3309. ISSN 8756-7938.
  22. ^ "Packing quality, protein binding capacity and separation efficiency of pre-packed columns ranging from 1 mL laboratory to 57 L industrial scale". Journal of Chromatography A. 1591: 79–86. 2019-04-26. doi:10.1016/j.chroma.2019.01.014. ISSN 0021-9673.
  23. ^ Koch, Jonas; Scheps, Daniel; Gunne, Matthias; Boscheinen, Oliver; Frech, Christian (2023-02-27). "Mechanistic modeling of cation exchange chromatography scale‐up considering packing inhomogeneities". Journal of Separation Science. 46 (9). doi:10.1002/jssc.202300031. ISSN 1615-9306.
  24. ^ Tona, Robert M.; Shah, Reeti; Middaugh, Kimberly; Steve, Justin; Marques, João; Roszell, Blair R.; Jung, Cindy (2023-06-08). "Process intensification for lentiviral vector manufacturing using tangential flow depth filtration". Molecular Therapy. Methods & Clinical Development. 29: 93–107. doi:10.1016/j.omtm.2023.02.017. ISSN 2329-0501. PMC 10041461. PMID 36994313.
  25. ^ "Time-dependent particle size increase during lipid nanoparticle purification by cross-flow filtration". Journal of Colloid and Interface Science. 694 137663. 2025-09-15. doi:10.1016/j.jcis.2025.137663. ISSN 0021-9797.
  26. ^ "Repligen Launches the CTech™ SoloVPE® PLUS System". investors.repligen.com. Retrieved 2025-10-10.
  27. ^ Bhangale, Rashmi P.; Ye, Rui; Lindsey, Thomas B.; Wolfe, Leslie S. (2022-02-02). "Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals". Biotechnology Progress. 38 (2) e3236. doi:10.1002/btpr.3236. ISSN 1520-6033. PMC 9285919. PMID 35064963.
  28. ^ "Repligen Acquires Bioprocessing Business of Refine Technology". BioProcess International. Retrieved 2025-10-10.
  29. ^ Corporation, Repligen (2020-10-27). "Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions". GlobeNewswire News Room. Retrieved 2025-10-10.

Sources

[edit]
[edit]

Official website

  • Business data for Repligen Corporation:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Repligen&oldid=1356905113"